With reference to the above captioned subject, we wish to intimate your esteemed exchange that as decided in the Meeting of the Board of Directors of the Company held today, i.e., on May, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Clinitech Laboratory Ltd reported audited standalone revenue of Rs 947.50 Lakhs for FY2026, up 15% from Rs 823.49 Lakhs in FY2025. Profit after tax grew 7% to Rs 42.25 Lakhs from Rs 39.47 Lakhs. The Board meeting held on May 28, 2026 approved these results along with consolidated financials which showed PAT of Rs 41.79 Lakhs. Statutory auditors Kale Malde & Co issued an unmodified (clean) opinion on both standalone and consolidated statements. The company also took note of related party transactions for FY2026 and approved estimated RPTs for FY2027. The IPO proceeds utilization certificate shows Rs 528.30 Lakhs deployed out of Rs 578.30 Lakhs raised, with Rs 50 Lakhs remaining unutilized.
The clean audit opinion and steady revenue growth of 15% are positive signals for investors. The small decline in EPS from Rs 1.90 to Rs 1.85 despite PAT growth indicates possible share count changes. The unutilized IPO funds of Rs 50 Lakhs remain deployed in short-term deposits.